Klas R Linderholm
Overview
Explore the profile of Klas R Linderholm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Linderholm K, Alm M, Larsson M, Olsson S, Goiny M, Hajos M, et al.
Neuropharmacology
. 2015 Oct;
102:42-7.
PMID: 26514401
Kynurenic acid (KYNA), a neuroactive metabolite of tryptophan, is elevated in the brain of patients with psychotic disorders. Therefore, lowering brain KYNA levels might be a novel approach in the...
2.
Bay-Richter C, Linderholm K, Lim C, Samuelsson M, Traskman-Bendz L, Guillemin G, et al.
Brain Behav Immun
. 2014 Aug;
43:110-7.
PMID: 25124710
Background: Patients with depression and suicidality suffer from low-grade neuroinflammation. Pro-inflammatory cytokines activate indoleamine 2,3-dioxygenase, an initial enzyme of the kynurenine pathway. This pathway produces neuroactive metabolites, including quinolinic- and...
3.
Erhardt S, Lim C, Linderholm K, Janelidze S, Lindqvist D, Samuelsson M, et al.
Neuropsychopharmacology
. 2013 Jan;
38(5):743-52.
PMID: 23299933
The NMDA-receptor antagonist ketamine has proven efficient in reducing symptoms of suicidality, although the mechanisms explaining this effect have not been detailed in psychiatric patients. Recent evidence points towards a...
4.
Linderholm K, Skogh E, Olsson S, Dahl M, Holtze M, Engberg G, et al.
Schizophr Bull
. 2010 Aug;
38(3):426-32.
PMID: 20729465
Background: The kynurenic acid (KYNA) hypothesis for schizophrenia is partly based on studies showing increased brain levels of KYNA in patients. KYNA is an endogenous metabolite of tryptophan (TRP) produced...
5.
Olsson S, Andersson A, Linderholm K, Holtze M, Nilsson-Todd L, Schwieler L, et al.
Int J Neuropsychopharmacol
. 2008 Sep;
12(4):501-12.
PMID: 18796185
Kynurenic acid (KYNA) is an endogenous compound implicated in the pathophysiology of schizophrenia. This tryptophan metabolite antagonizes both the N-methyl-D-aspartate (NMDA) receptors and the nicotinic alpha7* receptors at micromolar concentrations....
6.
Schwieler L, Linderholm K, Nilsson-Todd L, Erhardt S, Engberg G
Life Sci
. 2008 Jul;
83(5-6):170-5.
PMID: 18590745
Clozapine has a remarkable efficacy in treatment-resistant schizophrenia and is one of the most effective antipsychotic drugs used today. The clinical effects of clozapine are suggested to be related to...
7.
Linderholm K, Andersson A, Olsson S, Olsson E, Snodgrass R, Engberg G, et al.
Neuropharmacology
. 2007 Oct;
53(8):918-24.
PMID: 17959203
Kynurenic acid (KYNA) is an endogenous NMDA receptor antagonist as well as a blocker of the alpha7* nicotinic receptor and mounting evidence suggests that the compound participates in the pathophysiology...
8.
Nilsson L, Nordin C, Jonsson E, Engberg G, Linderholm K, Erhardt S
J Psychiatr Res
. 2006 Jan;
41(1-2):144-51.
PMID: 16434056
The concentrations of the tryptophan metabolite kynurenic acid (KYNA) and the monoamine metabolites homovanillic acid (HVA), 5-hydroxy-indoleacetic acid (5-HIAA) and 4-hydroxy-3-methoxyphenylglycol (HMPG) were determined in the cerebrospinal fluid (CSF) from...
9.
Nilsson L, Schwieler L, Engberg G, Linderholm K, Erhardt S
Int J Neuropsychopharmacol
. 2005 Mar;
8(3):329-39.
PMID: 15737250
The major brain noradrenergic nucleus locus coeruleus (LC) has long been thought to be involved in states of alertness and cognitive processes. These functional characteristics make this nucleus interesting with...